8
Hepatitis web study Source: Jacobson I, et al. N Engl J Med. 2013;368: Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 FUSION Trial: Conclusions Conclusions: “Our findings suggest that 12 weeks of treatment with sofosbuvir and ribavirin can be an effective option for patients with HCV genotype 2 infection. However, for patients with genotype 3 infection, particularly those who have cirrhosis or who have not had a response to prior treatment with interferon, extending the duration of treatment to 16 weeks may provide an additional benefit.” *Note: This conclusion pertains to both the FUSION and POSITRON trials, which were published in tandem

9
Hepatitis web study Hepatitis web study This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online Hepatitis Web Study Funded by a grant from the Centers for Disease Control and Prevention. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online Hepatitis Web Study Funded by a grant from the Centers for Disease Control and Prevention.